An Open-Label, Multi-Centre, Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of 2-Week Treatment with Inhaled AZD7594 in Adolescents (12 to 17 years) with Asthma
12 Years - 17 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Verified 01 Jan 2021 by AstraZeneca
No locations available
|Experimental: Cohort 1|
The study will include adolescent patients of 12 to 17 years of age, with subgroups of 12-14 years age and 15-17 years age.
During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).